Zevra Therapeutics, Inc.

ZVRA Nasdaq SEC CIK 1434647
Follow Zevra Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $37.8M +44.9% vs same quarter last year
Net income $19.2M +3630.9% vs same quarter last year
EPS, diluted $0.26 +2700% vs same quarter last year
Operating cash flow $10M +113.4% vs same quarter last year
Revenue by quarter
$12M
$20.4M
$25.9M
$26.1M
$34.1M
$36.2M
$39.7M
$37.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$106.5M$83.2M
FY24$23.6M−$105.5M
FY23$27.5M−$46M
FY22$10.2M−$26.8M
FY21$28.7M−$8.6M
FY20$13.3M−$12.8M
FY19$12.8M−$24.5M
FY18$0−$56.5M
FY17-−$43.4M
FY16-−$16.5M
FY15$0−$54.7M
FY14$0−$24.5M
FY13$0−$5.2M
FY12--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−59.1%78.2%
FY24-−368.5%−446.9%
FY2389.3%−180.6%−167.7%
FY2297.8%−418.9%−263.5%
FY2192.8%27%−29.9%
FY20-−42.2%−96%
FY1922.1%−158.4%−191%
FY18---
FY17---
FY16---
FY15---
FY14---
FY13---
FY12---
Free cash flowOperating cash flow minus capital expenditure
−$75M−$50M−$25M$0$25MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$2.4M
FY24−$69.7M
FY23−$33.8M
FY22−$18.8M
FY21$10.3M
FY20−$2M
FY19−$23.8M
FY18−$54.2M
FY17−$33.3M
FY16−$30.4M
FY15−$20.4M
FY14−$14.7M
FY13−$4.4M
FY12-
Returned to shareholdersDividends paid and shares bought back
$0$2M$4M$6MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24$0
FY23$3.4M
FY22$4.7M
FY21$2.8M
FY20$0
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Zevra Therapeutics
  • Healthcare median
−600%−400%−200%0%200%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearZevra TherapeuticsHealthcare median
FY2578.2%−30.6%
FY24−446.9%−47%
FY23−167.7%−58%
FY22−263.5%−80.4%
FY21−29.9%−71.8%
FY20−96%−62.2%
FY19−191%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%